---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-084520"
form_type: "8-K"
ticker: "TCRT"
cik: "0001107421"
company_name: "Alaunos Therapeutics, Inc."
filed_at: "2023-03-30T23:59:59+00:00"
generated_at: "2026-06-17T08:54:02.586130+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Alaunos Therapeutics appoints Dr. Robert Hofmeister to board, replacing Dr. Christopher Bowden

## Summary
- Christopher Bowden resigned from board effective March 30, 2023; no disagreement with company.
- Robert Hofmeister appointed as director effective March 30, 2023, filling Bowden's vacancy.
- Hofmeister brings over 25 years of T-cell therapy experience; previously CSO at TCR2 Therapeutics.
- Hofmeister receives initial option for 150,000 shares and pro-rated annual grant for 16,667 shares.
- Hofmeister appointed to Corporate Governance and Nominating and Compensation Committees.

## SEC filing metadata
- accession: 0001193125-23-084520
- form_type: 8-K
- ticker: TCRT
- cik: 0001107421
- company_name: Alaunos Therapeutics, Inc.
- filed_at: 2023-03-30T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1107421/000119312523084520/0001193125-23-084520-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1107421/000119312523084520/d490816d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-084520
- JSON: https://secwatch.observer/filing/0001193125-23-084520.json
- Plain text: https://secwatch.observer/filing/0001193125-23-084520.txt

## Key facts
- Executive change
  Christopher Bowden resigned as Director at Alaunos Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: Christopher Bowden, M.D. delivered notice of his resignation from the board of directors (the “Board”) of Alaunos Therapeutics, Inc. (the “Company”), effective March 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1107421/000119312523084520/0001193125-23-084520-index.htm
- Executive change
  Robert Hofmeister was appointed as Director at Alaunos Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: the Board appointed Robert Hofmeister, Ph.D., as a director of the Company effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1107421/000119312523084520/0001193125-23-084520-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.